everolimus mylan 2,5 mg tabletten
mylan germany gmbh (8185157) - everolimus - tablette - teil 1 - tablette; everolimus (29196) 2,5 milligramm
omeprazol mylan 40 mg magensaftresistente hartkapseln
mylan germany gmbh (8185157) - omeprazol - magensaftresistente hartkapsel - teil 1 - magensaftresistente hartkapsel; omeprazol (22284) 40 milligramm
omeprazol mylan 10 mg magensaftresistente hartkapseln
mylan germany gmbh (8185157) - omeprazol - magensaftresistente hartkapsel - teil 1 - magensaftresistente hartkapsel; omeprazol (22284) 10 milligramm
omeprazol mylan 20 mg magensaftresistente hartkapseln
mylan germany gmbh (8185157) - omeprazol - magensaftresistente hartkapsel - teil 1 - magensaftresistente hartkapsel; omeprazol (22284) 20 milligramm
risperidon mylan 4 mg filmtabletten
mylan germany gmbh (8185157) - risperidon - filmtablette - risperidon (24756) 4 milligramm
risperidon mylan 3 mg filmtabletten
mylan germany gmbh (8185157) - risperidon - filmtablette - risperidon (24756) 3 milligramm
risperidon mylan 1 mg filmtabletten
mylan germany gmbh (8185157) - risperidon - filmtablette - risperidon (24756) 1 milligramm
risperidon mylan 0,5 mg filmtabletten
mylan germany gmbh (8185157) - risperidon - filmtablette - risperidon (24756) 0,5 milligramm
risperidon mylan 2 mg filmtabletten
mylan germany gmbh (8185157) - risperidon - filmtablette - risperidon (24756) 2 milligramm
emtricitabine/tenofovir disoproxil mylan
mylan pharmaceuticals limited - emtricitabin, tenofovir disoproxil maleate - hiv-infektionen - antivirale mittel zur systemischen anwendung - treatment of hiv-1 infection:emtricitabine/tenofovir disoproxil mylan is indicated in antiretroviral combination therapy for the treatment of hiv-1 infected adults (see section 5. emtricitabine/tenofovir disoproxil mylan is also indicated for the treatment of hiv-1 infected adolescents, with nrti resistance or toxicities precluding the use of first line agents, (see sections 4. 2, 4. 4 und 5. pre-exposure prophylaxis (prep):emtricitabine/tenofovir disoproxil mylan is indicated in combination with safer sex practices for pre-exposure prophylaxis to reduce the risk of sexually acquired hiv-1 infection in adults and adolescents at high risk (see sections 4. 2, 4. 4 und 5.